Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Skin Neoplasms

Skin Diseases

Micronutrients

All Drugs and Chemicals

Antineoplastic Agents

Vasodilator Agents

Lipid Regulating Agents

Hematinics

Vitamins

Vitamin A

Retinol palmitate

Niacinamide

Niacin

Nicotinic Acids

Vitamin B Complex

Trace Elements

Folic Acid

Retinol

Nicotinamide

Nicotinic Acid

Vitamin B3

Folate

Vitamin B9

1,000 μg retinyl palmitate and 500 mg NAM twice a day

1,000 μg retinyl palmitate twice a day for 6 months

Other: Placebo

Eunyoung Cho, ScD

The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide (NAM; a derivative of vitamin B3 \[niacin\]) and vitamin A in a high-risk population of kidney transplant recipients with a history of skin cancer to generate preliminary data for future cancer prevention clinical trials.

Pilot Trial of Supplemental Vitamin A and Nicotinamide

Pilot Trial of Supplemental Vitamin A and Nicotinamide and Levels of Blood Vitamin A and Nicotinamide

Rhode Island Hospital

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Donata Villari, MD

Donata Villari

Kidney transplantation is considered the standard of care for patients with end-stage kidney disease under chronic dialysis treatment. Today, modern surgical techniques have dramatically improved the quality of life and the overall survival of renal transplant recipients (RTRs) . Besides, the use of novel immunosuppressors have increased the 1-year graft survival rate and decreased acute rejection rate . Unfortunately, several transplantation-related diseases including cancer, cardiovascular disease and infection may affect the survival of renal transplant recipients. It has been estimated that RTRs are 2- to 5- fold more likely to develop cancer compared to the general population. Therefore, the development of cancer has become a major concern as it is currently one of the main causes of death in RTRs. The increasing incidence of post-transplant malignancies is generally attributed to immunosuppression which leads to impaired immunosurveillance of cancer cells and virals infections capable of cancer development. Additionally, it has been observed a direct and specific pro-oncogenic effect on RTRs of immunosuppressive drugs and other immunosuppression-independent factors such as the increased age of RTRs, the male gender and the pre-transplant dialysis duration . Prostate cancer is the second most diagnosed cancer in men and the most common non-skin solid neoplasm in RTRs. Generally, the vast majority of post kidney transplantation prostate cancers are localised; however, due to the lack of randomized studies, no specific guidelines for the management of localized prostate cancer are available and, consequently, RTR patients are being treated with surgery or radiotherapy according to national or local guidelines. The concomitant use of immunosuppressors and the presence of the kidney graft in the pelvic cavity make the treatment of localised prostate cancer post kidney transplantation more challenging, highlighting the need for these patients to be addressed to urological oncology centres with surgeons familiar with oncological and transplant surgery.

Prostate cancer is the second most diagnosed cancer in men and the most common non-skin solid neoplasm in RTRs, however, little studies describe the real incidence of prostate cancer in RTRs.

The aim of this study is to retrospectively review a 25-year experience at the Florence Transplant Center in order to evaluate the incidence of prostate cancer and its possible clinical/pathological factors able to influence the survival.

Prostate Cancer in Renal Transplants Recipients

Incidence and Clinical-pathological Characteristics of Prostate Cancer in Kidney Transplants Recipients ( KTRs)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pilot Trial of Supplemental Vitamin A and Nicotinamide	NCT05702398	Skin Cancer Kidney Transpla...	Vitamin A Nicotinamide Other: Placebo	18 Years -	Rhode Island Hospital
Prostate Cancer in Renal Transplants Recipients	NCT04642833	Prostate Cancer Renal Transplan... Kidney Transpla...		40 Years - 80 Years	University of Florence
Pilot Trial of Supplemental Vitamin A and Nicotinamide	NCT05702398	Skin Cancer Kidney Transpla...	Vitamin A Nicotinamide Other: Placebo	18 Years -	Rhode Island Hospital

Spots Global Cancer Trial Database for kidney transplant recipients